ImmunoMet Therapeutics
Phase 1News Release ImmunoMet Therapeutics Presents Updated Clinical Data from Phase1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting January 24, 2025 – Houston, Texas
Founded
2015
Focus
Small Molecules
About
News Release ImmunoMet Therapeutics Presents Updated Clinical Data from Phase1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting January 24, 2025 – Houston, Texas
Funding History
2Total raised: $22M
Series A$17MBoehringer Ingelheim Venture FundJun 15, 2021
Seed$5MUndisclosedJun 15, 2018
Company Info
TypePrivate
Founded2015
LocationHouston, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile